Last reviewed · How we verify
Metoprolol- Toprol XL
At a glance
| Generic name | Metoprolol- Toprol XL |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score (PHASE4)
- Bariatric Surgery and Pharmacokinetics of Metoprolol
- Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects (PHASE4)
- Comparison of Blood Pressure Medications on Metabolism (PHASE4)
- Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart (PHASE4)
- Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure (PHASE2)
- Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (PHASE3)
- Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metoprolol- Toprol XL CI brief — competitive landscape report
- Metoprolol- Toprol XL updates RSS · CI watch RSS
- AstraZeneca portfolio CI